拉贝洛尔联合硝苯地平缓释片治疗妊娠期高血压的效果观察OA
Observation on the Effect of Labetalol Combined with Nifedipine Sustained-Release Tablets in the Treatment of Hypertension During Pregnancy
目的:探讨拉贝洛尔联合硝苯地平缓释片治疗妊娠期高血压(HDP)的效果.方法:选取 2021年 9月—2023年 11月聊城市东昌府区妇幼保健院收治的 86例HDP患者为研究对象,按随机数字表法将其分为对照组及研究组,各43例.对照组采用拉贝洛尔治疗,研究组在此基础上采用硝苯地平缓释片治疗.两组均治疗 7 d.比较两组治疗效果、血压水平、脐动脉血流动力学、血清学指标及不良反应发生情况.结果:研究组的治疗总有效率为 95.35%,高于对照组的 81.40%,差异有统计学意义(P<0.05).治疗后,研究组的收缩压(SBP)、舒张压(DBP)分别为(129.57±7.45)mmHg、(85.36±6.81)mmHg,均低于对照组的(141.37±8.92)mmHg、(96.28±8.02)mmHg,差异均有统计学意义(P<0.05).治疗后,研究组的血浆黏度、脐动脉SBP与DBP的血流峰速比、阻力指数、血细胞比容分别为(2.86±0.43)mPa·s、(1.67±0.20)、(0.29±0.08)%、(32.22±3.57)%,均低于对照组的(3.39±0.51)mPa·s、(2.01±0.37)%、(0.37±0.10)%、(37.44±4.19)%,差异均有统计学意义(P<0.05).治疗后,研究组的C反应蛋白、同型半胱氨酸水平均分别为(10.13±1.44)μmmol/L、(6.27±1.18)mg/L,均低于对照组的(13.22±2.53)μmmol/L、(8.03±1.37)mg/L,差异均有统计学意义(P<0.05).研究组的不良反应发生率为 4.65%,低于对照组的 9.30%,但两组间比较,差异无统计学意义(P>0.05).结论:拉贝洛尔联合硝苯地平缓释片可更好地控制HDP患者的血压水平,改善其脐动脉血流动力学、血清学指标,安全有效.
Objective:To investigate the effect of Labetalol combined with Nifedipine Sustained-Release Tablets in the treatment of hypertension during pregnancy(HDP).Methods:A total of 86 HDP patients admitted to Liaocheng Dongchangfu Maternal and Child Health Hospital from September 2021 to November 2023 were selected as the study objects and were divided into a control group and a study group according to random number table method,with 43 cases in each group.The control group was treated with Labetalol,and the study group was treated with Nifedipine Sustained-Release Tablets on this basis.Both groups we no tiveated 7 d.The therapeutic effect,blood pressure levels,umbilical artery hemodynamics,serological indexes and occurrence of adverse reactions of the two groups were compared.Results:The total effective rate of the study group was 95.35%,which was higher than 81.40%of the control group,the difference was statistically significant(P<0.05).After treatment,the systolic blood pressure(SBP)and diastolic blood pressure(DBP)of the study group were(129.57±7.45)mmHg and(85.36±6.81)mmHg,respectively,which were lower than(141.37±8.92)mmHg and(96.28±8.02)mmHg of the control group,the differences were statistically significant(P<0.05).After treatment,the plasma viscosity,peak velocity ratio of umbilical artery SBP to DBP,resistance index and hematocrit in the study group were(2.86±0.43)mPa·s,(1.67±0.20)%,(0.29±0.08)%and(32.22±3.57)%,respectively,which were lower than(3.39±0.51)mPa·s,(2.01±0.37)%,(0.37±0.10)%and(37.44±4.19)%in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of C-reactive protein and homocysteine in the study group were(10.13±1.44)μmmol/L and(6.27±1.18)mg/L,respectively,which were lower than(13.22±2.53)μmmol/L and(8.03±1.37)mg/L in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 4.65%,which was lower than 9.30%in the control group,but there was no statistical significance between the two groups(P>0.05).Conclusion:Labetalol combined with nifedipine sustained-release Tablets can better control the blood pressure of HDP patients,improve their umbilical artery hemodynamics and serological indexes,and is safe and effective.
李凌洁;张琳琳
山东省聊城市东昌府区妇幼保健院产科,山东 聊城 252000山东省聊城市东昌府区妇幼保健院产科,山东 聊城 252000
医药卫生
妊娠期高血压拉贝洛尔硝苯地平缓释片治疗效果血压脐动脉血流动力学
Hypertension during pregnancyLabetalolNifedipine Sustained-Release TabletsTherapeutic effectBlood pressureUmbilical artery hemodynamics
《中国伤残医学》 2025 (5)
64-67,4
评论